Roche Holdings Ltd ADR (RHHBY)

$54.12 +0.16 (0.30%)
Market Cap 339.80B
Revenue (ttm) 70.87B
Net Income (ttm) 9.40B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 17.34
Profit Margin 13.27%
Debt to Equity Ratio 1.00
Volume 3,010,645
Avg Vol 2,597,604
Day's Range N/A - N/A
Shares Out 6.37B
Stochastic %K 97%
Beta 0.44
Analysts Sell
Price Target $51.58

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
Quantumup
Quantumup Jan. 15 at 6:54 PM
Morgan Stanley reit'd $IRON OW/$120—says 'Buy The Dip' after mgmt.🗣️w/ analyst to discuss the unconfirmed Reuters report that the FDA has extended the review for several CNPV Tx's. $SNY $RHHBY $LLY Stifel: IRON: Buy; $125—Views weakness as Buying opp. Wedbush: IRON: OP; $110—sees limited risk to bitopertin's eventual approval—buying opportunity. Here's what the Analysts had to say:
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 15 at 3:35 PM
$SLS $BMY $RHHBY These are the days, bio-Red, market manipulation - when INVESTORS Take advantage. We all will wish we got more down here when the P3 results are Announced.
0 · Reply
MQuick
MQuick Jan. 15 at 1:30 PM
$GANX $SNY $RHHBY $MRK wake up!
0 · Reply
cielo1
cielo1 Jan. 15 at 7:58 AM
$IFRX https://www.amgenoncology.com/targets/C5.html Let's see it amgen! $AMGN $MRK $RHHBY Genentech So many uses, who is going to bring Gohibic and Izicopan to patients world wide? 🌎
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 15 at 5:13 AM
$SLS $BMY $RHHBY
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 14 at 10:37 PM
$SLS As an FYI for the Passersby, Gps Phase 3 MOS is 100% for Sure Longer than the Statistically Significant 21 month result. - and Aza+VEN the BAT for Control ARM patients is Toxic as F and Recently FAILED 3 Large Phase 3 AML Trials VIALE-T Failed, VERONA Failed, VIALE-M Failed - M for First Remission Maintenance - Aza+Ven also Failed the SLS Phase 3 CONTROL ARM Patients. https://www.reddit.com/r/sellasLifescience/comments/1q6izvc/if_you_are_interested_in_knowing_gps_phase_3/?share_id=yj9ty6n4B_kfvV4Sp1y-c&utm_content=4&utm_medium=ios_app&utm_name=ioscss&utm_source=share&utm_term=1 if you don’t know Gps is the reason we are seeing near miraculous survival in ALL POOLED SLS P3 patients, you need to do to more DD. - Many Players Paying attention, esp $ABBV $BMY $RHHBY absolutely Know Gps is Getting FDA Approval, and SLS is worth closer to $40B than the current manipulated .67b.
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 14 at 10:26 PM
$SLS $BMY $RHHBY Got the Jpm 009 PR/// How long is too long to wait for Phase 3 Results worth $40B to Big Pharma? Current mcap $.67B 60X ROI 60,000 Potential Return
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 14 at 4:18 PM
$SLS AML-MR is the Highest Unmet Need in all AML and First and Only safe CDK9 Inhibitor. 4X Survival Advantage for the Most Unmet Need in AML, Post Ven HMA treatment failure dying patients who have failed all treatments with a 2.5 month life expectancy. $RHHBY just bought REGOR CDK Phase 1 asset - for $850M +$4B In future Payments $PFE $143B Ibrance - Palbociclib CDKinase Inhibitor $NVS $274B Kisqali - Ribociclib CDKinase Inhibitor $LLY $970B Verzenio - Abemaciclib CDKinase Inhibitor $SLS $.68B Tambiciclib CDKInase Inhibitor SLS009 is in the Class and Category of Many CDK Inhibitor Blockbuster Drugs with House Hold names. - Massively Undervalued Asset.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 13 at 3:48 PM
$SLS $BMY $RHHBY Buyout Rumors swirling at the JPM Conference.
1 · Reply
Quantumup
Quantumup Jan. 13 at 1:18 PM
Piper Sandler⬆️ $ARWR's PT to $110 and reit'd at Overweight $IONS $WVE $RHHBY $REGN TEVA Piper Sandler said in its note: Arrowhead launched Redemplo for familial chylomicronemia syndrome (FCS), and we conservatively forecast sales of $8.4 million in FY:26 to grow to $41.6 million in FY:27. We are confident Arrowhead will report positive Phase III Redemplo data in severe hypertriglyceridemia in 3Q:26 with potential blockbuster label expansion in CY:27. Arrowhead reported impressive weight and fat loss data from the ongoing Phase I/II studies of ARO-INHBE and ARO-ALK7 with more data this year. Arrowhead initiated Phase I/ lla studies of ARO-DIMER-PA for ASCVD and ARO-MAPT for early Alzheimer's disease patients, both with initial data in 2026. Arrowhead issued $700 million in zero coupon convertible debt and raised $230 million in equity bringing pro forma cash to ~$2.09 billion and debt to ~$955 million. We reiterate our Overweight rating and are increasing our price target to $110 from $100.
1 · Reply
Latest News on RHHBY
No data available.
Quantumup
Quantumup Jan. 15 at 6:54 PM
Morgan Stanley reit'd $IRON OW/$120—says 'Buy The Dip' after mgmt.🗣️w/ analyst to discuss the unconfirmed Reuters report that the FDA has extended the review for several CNPV Tx's. $SNY $RHHBY $LLY Stifel: IRON: Buy; $125—Views weakness as Buying opp. Wedbush: IRON: OP; $110—sees limited risk to bitopertin's eventual approval—buying opportunity. Here's what the Analysts had to say:
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 15 at 3:35 PM
$SLS $BMY $RHHBY These are the days, bio-Red, market manipulation - when INVESTORS Take advantage. We all will wish we got more down here when the P3 results are Announced.
0 · Reply
MQuick
MQuick Jan. 15 at 1:30 PM
$GANX $SNY $RHHBY $MRK wake up!
0 · Reply
cielo1
cielo1 Jan. 15 at 7:58 AM
$IFRX https://www.amgenoncology.com/targets/C5.html Let's see it amgen! $AMGN $MRK $RHHBY Genentech So many uses, who is going to bring Gohibic and Izicopan to patients world wide? 🌎
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 15 at 5:13 AM
$SLS $BMY $RHHBY
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 14 at 10:37 PM
$SLS As an FYI for the Passersby, Gps Phase 3 MOS is 100% for Sure Longer than the Statistically Significant 21 month result. - and Aza+VEN the BAT for Control ARM patients is Toxic as F and Recently FAILED 3 Large Phase 3 AML Trials VIALE-T Failed, VERONA Failed, VIALE-M Failed - M for First Remission Maintenance - Aza+Ven also Failed the SLS Phase 3 CONTROL ARM Patients. https://www.reddit.com/r/sellasLifescience/comments/1q6izvc/if_you_are_interested_in_knowing_gps_phase_3/?share_id=yj9ty6n4B_kfvV4Sp1y-c&utm_content=4&utm_medium=ios_app&utm_name=ioscss&utm_source=share&utm_term=1 if you don’t know Gps is the reason we are seeing near miraculous survival in ALL POOLED SLS P3 patients, you need to do to more DD. - Many Players Paying attention, esp $ABBV $BMY $RHHBY absolutely Know Gps is Getting FDA Approval, and SLS is worth closer to $40B than the current manipulated .67b.
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 14 at 10:26 PM
$SLS $BMY $RHHBY Got the Jpm 009 PR/// How long is too long to wait for Phase 3 Results worth $40B to Big Pharma? Current mcap $.67B 60X ROI 60,000 Potential Return
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 14 at 4:18 PM
$SLS AML-MR is the Highest Unmet Need in all AML and First and Only safe CDK9 Inhibitor. 4X Survival Advantage for the Most Unmet Need in AML, Post Ven HMA treatment failure dying patients who have failed all treatments with a 2.5 month life expectancy. $RHHBY just bought REGOR CDK Phase 1 asset - for $850M +$4B In future Payments $PFE $143B Ibrance - Palbociclib CDKinase Inhibitor $NVS $274B Kisqali - Ribociclib CDKinase Inhibitor $LLY $970B Verzenio - Abemaciclib CDKinase Inhibitor $SLS $.68B Tambiciclib CDKInase Inhibitor SLS009 is in the Class and Category of Many CDK Inhibitor Blockbuster Drugs with House Hold names. - Massively Undervalued Asset.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 13 at 3:48 PM
$SLS $BMY $RHHBY Buyout Rumors swirling at the JPM Conference.
1 · Reply
Quantumup
Quantumup Jan. 13 at 1:18 PM
Piper Sandler⬆️ $ARWR's PT to $110 and reit'd at Overweight $IONS $WVE $RHHBY $REGN TEVA Piper Sandler said in its note: Arrowhead launched Redemplo for familial chylomicronemia syndrome (FCS), and we conservatively forecast sales of $8.4 million in FY:26 to grow to $41.6 million in FY:27. We are confident Arrowhead will report positive Phase III Redemplo data in severe hypertriglyceridemia in 3Q:26 with potential blockbuster label expansion in CY:27. Arrowhead reported impressive weight and fat loss data from the ongoing Phase I/II studies of ARO-INHBE and ARO-ALK7 with more data this year. Arrowhead initiated Phase I/ lla studies of ARO-DIMER-PA for ASCVD and ARO-MAPT for early Alzheimer's disease patients, both with initial data in 2026. Arrowhead issued $700 million in zero coupon convertible debt and raised $230 million in equity bringing pro forma cash to ~$2.09 billion and debt to ~$955 million. We reiterate our Overweight rating and are increasing our price target to $110 from $100.
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 13 at 7:52 AM
$SLS $BMY $RHHBY SLS009 news is due, Expected to coincide with the JPM Conference - this week. - and the fact is after the Holidays, we are now at 77/78 events, Thanksgiving, Christmas and New Years post holiday events. Smart money knows this, and that P3 results will be announced before we know it, and when they do, $47 will be cheap. - only inch thick mile wide retail lemming tools - with the forethought of Gold FISH don't have clue what it means to actually INVEST... and get in Early and CHEAP -- like right now. https://www.reddit.com/r/sellasLifescience/s/469bdHkImx
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:52 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:52 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
2 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint$LMDX
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:50 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
1 · Reply